IbrutinibMeSH concept

https://www.has-sante.fr/jcms/p_3332332/fr/imbruvica-ibrutinib
2022
false
false
false
France
drug recalls
capsules
evaluation of the transparency committee
ibrutinib
ibrutinib

---
https://www.has-sante.fr/jcms/p_3240237/fr/imbruvica-leucemie-lymphoide-chronique-llc
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
ibrutinib
ibrutinib
ibrutinib
guidelines for drug use
leukemia, lymphocytic, chronic, B-Cell
antineoplastic combined chemotherapy protocols
Rituximab
Ibrutinib/Rituximab Regimen
administration, oral
antineoplastic agents
antineoplastic agents
adult
survival analysis
evaluation of the transparency committee
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3181104/fr/imbruvica
2020
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
drug therapy, combination
Rituximab
waldenstrom macroglobulinemia
ibrutinib
ibrutinib
administration, oral
protein kinase inhibitors
evaluation of the transparency committee
ibrutinib
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3165709
2020
France
evaluation of the transparency committee
ibrutinib
ibrutinib

---
https://www.has-sante.fr/jcms/p_3168611
2020
France
evaluation of the transparency committee
ibrutinib
ibrutinib

---
https://www.has-sante.fr/jcms/p_3168596
2020
France
evaluation of the transparency committee
ibrutinib
leukemia, lymphocytic, chronic, B-Cell
association
ibrutinib

---
https://www.has-sante.fr/portail/jcms/c_2770187/fr/imbruvica-lcm
https://www.has-sante.fr/portail/jcms/c_2770187/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk-lcm
2017
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
orphan drug production
ibrutinib
adult
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
lymphoma, mantle-cell
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
survival analysis
comparative effectiveness research
temsirolimus
guidelines for drug use
Progression-Free survival
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
carrier proteins
pyrazoles
pyrimidines
pyrazoles
pyrimidines
sirolimus
sirolimus
disease-free survival

---
http://www.has-sante.fr/portail/jcms/c_2746213/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2746213/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2017
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
ibrutinib
ibrutinib
administration, oral
treatment outcome
ibrutinib
adult
protein kinase inhibitors
protein kinase inhibitors
IBtk protein, human
IBtk protein, human
insurance, health, reimbursement
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins
carrier proteins

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1152
2017
false
false
false
false
Canada
French
critical appraisal or critical reading
ibrutinib
ibrutinib
ibrutinib
leukemia, lymphocytic, chronic, B-Cell
antineoplastic agents
antineoplastic agents
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
comparative effectiveness research
Progression-Free survival
chlorambucil
treatment outcome
survival analysis
Tyrosine Kinase Inhibitors
aged
ibrutinib
ibrutinib
disease-free survival

---
http://www.has-sante.fr/portail/jcms/c_2742289/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2742289/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2016
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
ibrutinib
adult
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
waldenstrom macroglobulinemia
guidelines for drug use
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins

---
http://www.has-sante.fr/portail/jcms/c_2049868/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2049868/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
orphan drug production
ibrutinib
adult
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
lymphoma, mantle-cell
leukemia, lymphocytic, chronic, B-Cell
leukemia, lymphocytic, chronic, B-Cell
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
carrier proteins
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63012197
2015
false
false
false
France
French
summary of product characteristics
package leaflet
ibrutinib
capsules
ibrutinib
ibrutinib
pyrazoles
pyrimidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Imbruvica
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ibrutinib
ibrutinib
drug approval
europe
antineoplastic agents
antineoplastic agents
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
lymphoma, mantle-cell
ibrutinib
leukemia, lymphocytic, chronic, B-Cell
administration, oral
capsules
IBtk protein, human
protein kinase inhibitors
protein kinase inhibitors
drug monitoring
continuity of patient care
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins

---